The independent source for health policy research, polling, and news.
401-420 of 704 results
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent âunapprovedâ and âmisbrandedâ drugs to U.S. consumers, jeopardizing their safety.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
KHN correspondent Emmarie Huetteman appeared on the C-SPAN program âWashington Journal,â where she fielded viewersâ calls about high drug prices and industry criticism.
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Jennifer Haberkorn of the Los Angeles Times join KHNâs Julie Rovner to discuss the new âMedicare-for-allâ bill introduced by House Democrats, the grilling of pharmaceutical company CEOs by a Senate committee and new Trump administration rules that take aim at Planned Parenthood. Plus, Rovner interviews KHNâs Julie Appleby about the latest âBill of the Monthâ installment.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Tuesdayâs Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
The stateâs governor said the plan has the full support of the White House. But the Trump administration was noncommittal about whether allowing states to buy and import cheaper drugs from up north could be the answer to the nationâs drug-pricing problem.
Most hearings before the U.S. House and Senate are routine affairs. But a few tense moments featuring everyone from Hillary Clinton to tobacco CEOs drew the attention of millions of Americans.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
Tuesdayâs Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
Confrontational hearings 60 years ago sparked remarkably similar quotes about drug prices and health care policy.
Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHNâs Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.
Medicare and many private insurers view prescribing drugs to improve sexual function as a lifestyle issue thatâs not medically necessary to pay for.
Unwilling to wait for federal action, California Gov. Gavin Newsom says he has a plan that could extract discounts from drugmakers and save the state money â one he hopes other states can join.
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
Health was a featured player in President Donald Trumpâs 2019 State of the Union address. The president set goals to bring down prescription drug prices, end the HIV epidemic in the U.S. and cure childhood cancer, among other things. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Alice Ollstein of Politico join KHNâs Julie Rovner to discuss these issues and, for âextra credit,â provide their favorite health policy stories of the week. Rovner also interviews KHN senior correspondent Phil Galewitz about the current âBill of the Monthâ feature.
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half havenât reached the market.
The president laid out a series of goals, including lowering prescription prices, pursuing an end to the HIV epidemic and boosting funding for childhood cancers.
Š 2026 KFF